
TCRX
USDTScan Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.170
Kõrge
$1.250
Madal
$1.080
Maht
0.81M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
63.6M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.51M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
BTIG Downgrades TScan Therapeutics to Neutral
BTIG analyst Justin Zelin downgrades TScan Therapeutics from Buy to Neutral.
Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
Needham analyst Gil Blum maintains TScan Therapeutics with a Buy and lowers the price target from $9 to $6.
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development;
Seotud aktsiad
FMNB
Farmers National Banc Corp.
AEHR
Aehr Test Systems
KNSA
Kiniksa Pharmaceuticals International plc Ordinary Shares
SNDR
Schneider National Inc.
PMTU
PennyMac Mortgage Investment Trust 8.50% Senior Notes due 2028
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.